Home›Trial›NCT05047094
NCT05047094NARECRUITING

Alpha Radiation Emitters Device (DaRT) in Combination With Check Point Inhibitor for the Treatment of Recurrent Unresectable or mHNSCC

Study Summary

A unique combinational treatment for cancer employing intratumoral diffusing alpha radiation emitter device with check point inhibitor for recurrent unresectable or metastatic Head and Neck Squamous Cell Carcinoma

Conditions
Head and Neck Squamous Cell CarcinomaSkin CancerMetastatic Head-and-neck Squamous-cell Carcinoma
Interventions / Drugs
Diffusing Alpha Radiation Emitters Therapy (DaRT)Pembrolizumab
View on ClinicalTrials.gov ↗
Sponsor
DRTS
Alpha Tau Medical Ltd.
Biotech / Pharma
F26/100
Study Details
Enrollment48 participants
Primary Completion—
Lead SponsorAlpha Tau Medical LTD.
Data Retrieved2026-06-17 02:56:49.846179+00:00
What This Trial Means for Biotech Investors
Trial Phase Context

This trial phase represents an early or specialized stage of clinical development.

Status & Expected Data

Currently recruiting: the trial is enrolling patients. A data readout is not expected until after enrollment closes and the follow-up period is complete.

Enrolled: 48 participants
Sponsor Catalyst Profile

Alpha Tau Medical Ltd. (DRTS) is the sponsoring company for this trial. BiotechSign currently grades this company F (26/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.

DRTS Full Pipeline →All Companies →
Not financial advice. BiotechSign data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.